Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration

• Status: Completed
• Trial end date: 2018-03-16
• Target enrollment: 0
• Participant gender: All

Summary

Patients with PKAN will be treated with the iron chelator deferiprone for 18 months. Only patients who have completed the earlier study TIRCON2012V1 (NCT01741532), a double-blind placebo-controlled trial in which participants were randomized to receive either deferiprone or placebo for 18 months, are eligible to enroll.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ApoPharma
• Treatments: Deferiprone; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Completed study TIRCON2012V1

Exclusion Criteria:

• Withdrew from the study TIRCON2012V1 for reasons of safety

• Plan to participate in another clinical trial at any time from the day of enrolment until 30 days post-treatment in the current study